0001179110-22-001517.txt : 20220222 0001179110-22-001517.hdr.sgml : 20220222 20220222174052 ACCESSION NUMBER: 0001179110-22-001517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220217 FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SALEKI-GERHARDT AZITA CENTRAL INDEX KEY: 0001563545 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22659621 MAIL ADDRESS: STREET 1: 1 N. WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 edgar.xml FORM 4 - X0306 4 2022-02-17 0 0001551152 AbbVie Inc. ABBV 0001563545 SALEKI-GERHARDT AZITA 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 EVP, Operations Common Stock, $0.01 par value 2022-02-17 4 A 0 25612 0 A 141896 D Common Stock, $0.01 par value 2022-02-17 4 A 0 5568 0 A 147464 D Common Stock, $0.01 par value 2022-02-17 4 A 0 11229 0 A 158693 D Common Stock, $0.01 par value 2022-02-17 4 A 0 7490 0 A 166183 D Common Stock, $0.01 par value 2022-02-17 4 A 0 13837 0 A 180020 D Common Stock, $0.01 par value 2322 I Profit sharing trust Common Stock, $0.01 par value 3873 I By spouse Option (Right to Buy) 144.54 2022-02-17 4 A 0 35026 0 A 2023-02-17 2032-02-16 Common Stock 35026 35026 D Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Balance in AbbVie Savings program as of January 31, 2022. The reporting person disclaims beneficial ownership of all securities held by her spouse. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025. Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt 2022-02-22